Stock EFTR EFFECTOR THERAPEUTICS, INC.
Add to a list

eFFECTOR Therapeutics, Inc. Stock

Stocks

EFTR

US28202V2079

Biotechnology & Medical Research

OTC Markets Traded
Market Closed -
OTC Markets
02:43:53 2026-10-06 pm EDT 		5-day change 1st Jan Change
0.000200 USD -75.00% Intraday chart for eFFECTOR Therapeutics, Inc. 0.00% -
24-09-10 Tyra Biosciences Names Doug Warner Chief Medical Officer MT
24-07-07 EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index CI

Valuation: eFFECTOR Therapeutics, Inc.

Market Cap 940 835.57 774.46 704.62 1.33K 89.21K 1.35K 9.31K 3.65K 46.55K 3.53K 3.45K 148K P/E 2022
-0.78x
P/E 2023 -0.71x
Enterprise Value 2.18M 1.93M 1.79M 1.63M 3.08M 207M 3.13M 21.55M 8.45M 108M 8.17M 7.99M 344M EV / Sales 2022
3,344,920x
EV / Sales 2023 -
Free-Float
99.75%
Yield 2022 *
-
Yield 2023 -
* Estimated data More valuation ratios

Chart: eFFECTOR Therapeutics, Inc.

Dynamic Chart

Latest news: eFFECTOR Therapeutics, Inc.

24-09-10 Tyra Biosciences Names Doug Warner Chief Medical Officer MT
24-07-07 EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index CI
24-07-01 EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index CI
24-06-24 Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
24-06-24 Top Midday Decliners MT
24-06-24 EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives MT
24-06-24 EFFECTOR Therapeutics, Inc. Announces Cessation of Michael Byrnes, Chief Financial Officer CI
24-06-24 Effector Therapeutics, Inc. Terminates Its Employees in Connection with the Planned Wind Down of the Company?s Operations CI
24-06-24 Effector Therapeutics, Inc. Announces Director Resignations CI
24-06-24 EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as CEO CI
24-06-24 EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board CI
24-05-20 EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer CI
24-05-09 EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
More news

Analysts' recommendations: eFFECTOR Therapeutics, Inc.

23-08-24 HC Wainwright Starts eFFECTOR Therapeutics With Buy Rating, $5 Price Target MT
23-05-26 Stifel Upgrades eFFECTOR Therapeutics to Buy From Hold, Adjusts Price Target to $7 From $1.30 MT
23-05-10 Credit Suisse Trims eFFECTOR Therapeutics' Price Target to $5.50 From $7, Keeps Outperform Rating MT
23-03-09 Credit Suisse Adjusts eFFECTOR Therapeutics' Price Target to $7 From $8, Keeps Outperform Rating MT
23-01-09 JMP Securities Trims Price Target on eFFECTOR Therapeutics to $1 From $2, Maintains Market Outperform Rating MT
More recommendations

Press Releases: eFFECTOR Therapeutics, Inc.

24-08-13 FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer AQ
24-06-26 EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K PU
24-06-24 EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq AQ
24-04-04 EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer AQ
24-02-05 EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference AQ
More press releases

Quotes and Performance

1 day-75.00%
3 months-66.67%
More quotes

Price Extremes

1 month 0
Extreme 0.0002
 0
Current year 0
Extreme 0.0002
 0
1 year 0
Extreme 0.0002
 0.02
3 years 0
Extreme 1.0E-6
 17.9
5 years 0
Extreme 1.0E-6
 307.5
10 years 0
Extreme 1.0E-6
 1,010.5
More quotes

Managers and Directors: eFFECTOR Therapeutics, Inc.

Manager TitleAgeSince
Craig Jalbert CEO
 Chief Executive Officer 65 2024-06-20
Director TitleAgeSince
Craig Jalbert BRD
 Director/Board Member 65 2024-06-20
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap. Importance
6/13/24
Brian Gallagher
Free

Chairman

800 0.0170%
6/13/24
Christopher Ehrlich
Free

Director

800 0.0170%
6/13/24
Kristen Harrington-Smith
Free

Director

800 0.0170%
Transaction History

Bio Therapeutic Drugs

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
EFFECTOR THERAPEUTICS, INC. Stock eFFECTOR Therapeutics, Inc.
-75.00%0.00%0.00%-100.00% 940
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-6.60%-8.56%+49.38%+63.51% 65B
LONZA GROUP AG Stock Lonza Group AG
+0.03%+5.56%+9.10%+69.05% 51.2B
ARGENX SE Stock argenx SE
-4.09%-0.11%+2.22%+53.15% 51.19B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.53%+2.70%+30.48%+34.12% 43.93B
BEONE MEDICINES AG Stock BeOne Medicines AG
-1.34%+4.12%+16.64%+115.13% 41.96B
REVOLUTION MEDICINES, INC. Stock Revolution Medicines, Inc.
-5.97%-6.22%+228.95%+454.22% 38.14B
CELLTRION, INC. Stock Celltrion, Inc.
+6.53%+8.02%+16.40%+53.41% 33.24B
WUXI BIOLOGICS (CAYMAN) INC. Stock WuXi Biologics (Cayman) Inc.
-0.90%-10.49%+37.09%-3.70% 25.2B
GENMAB A/S Stock Genmab A/S
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -8.99%-0.32%+40.97%+74.89% 37.24B
Weighted average by Cap. -2.20%-0.50%+44.25%+96.53%
See all sector performances

Financials

2022 2023
Net sales 3.55 3.16 2.93 2.66 5.03 337.21 5.11 35.19 13.8 175.97 13.33 13.05 560.96 -
Net income -22.66M -20.15M -18.67M -16.99M -32.06M -2.15B -32.57M -224M -88.01M -1.12B -85.06M -83.25M -3.58B -35.81M -31.83M -29.5M -26.84M -50.66M -3.4B -51.47M -355M -139M -1.77B -134M -132M -5.65B
Net Debt -6.03M -5.36M -4.97M -4.52M -8.53M -572M -8.66M -59.71M -23.41M -299M -22.63M -22.15M -952M 2.18M 1.93M 1.79M 1.63M 3.08M 206M 3.13M 21.54M 8.45M 108M 8.16M 7.99M 343M
Projected Income Statement - Annual - eFFECTOR Therapeutics, Inc.
* Estimated data More financial data

Company Profile

Logo eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
Employees
14
Sector
Biotechnology & Medical Research
More about the company

Quotes

Date Price Change Volume
26-10-16 $0.000000 - 30

Delayed Quote OTC Markets

More quotes

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - eFFECTOR Therapeutics, Inc.
Company calendar
  1. Stock Market
  2. Stocks
  3. EFTR Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong